Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $8.3600 (1.83%) ($8.1600 - $8.6400) on Mon. Oct. 12, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.86% (three month average) | RSI | 45 | Latest Price | $8.3600(1.83%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP declines -0.2% a day on average for past five trading days. | Weekly Trend | ADAP advances 2% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) UNG(19%) SDY(17%) XLP(16%) XLRE(16%) IWN(14%) | Factors Impacting ADAP price | ADAP will decline at least -2.43% in a week (0% probabilities). IPO(-17%) TIP(-14%) FXI(-14%) BNDX(-14%) BND(-14%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.43% (StdDev 4.86%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
Resistance Level | $8.64 | 5 Day Moving Average | $8.33(0.36%) | 10 Day Moving Average | $8.22(1.7%) | 20 Day Moving Average | $8.64(-3.24%) | To recent high | -22.4% | To recent low | 9.1% | Market Cap | $1.293b | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |